Farther Finance Advisors’s Cullinan Oncology CGEM Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$14.5K Buy
942
+93
+11% +$1.78K ﹤0.01% 4396
2026
Q2
$15.5K Buy
849
+244
+40% +$3.62K ﹤0.01% 4144
2026
Q1
$8.43K Buy
605
+45
+8% +$578 ﹤0.01% 4217
2025
Q4
$5.8K Buy
560
+423
+309% +$3.82K ﹤0.01% 4225
2025
Q3
$812 Sell
137
-1,228
-90% -$8.99K ﹤0.01% 4431
2025
Q2
$10.3K Buy
1,365
+352
+35% +$2.83K ﹤0.01% 3065
2025
Q1
$7.6K Buy
+1,013
New +$9.72K ﹤0.01% 2864

Other funds holding CGEM

Farther Finance Advisors's CGEM Position: Q3 2026 in Review

Farther Finance Advisors increased its Cullinan Oncology (CGEM) stake by 11% in Q3 2026, buying an estimated $1.78K and bringing the position to 942 shares worth $14.5K. The position accounts for ﹤0.01% of the portfolio, ranked #4396.

Farther Finance Advisors first reported a position in CGEM in Q1 2025 and has held it in 7 quarters since. The position peaked at $15.5K in Q2 2026. 4 funds tracked by Wall St. Rank hold CGEM as of Q3 2026.

  • Farther Finance Advisors held 942 shares of Cullinan Oncology worth $14.5K as of Q3 2026.
  • Farther Finance Advisors bought 93 Cullinan Oncology shares in Q3 2026, an estimated $1.78K.
  • Cullinan Oncology made up ﹤0.01% of Farther Finance Advisors's portfolio in Q3 2026, its #4396 holding.
  • Farther Finance Advisors first reported a position in Cullinan Oncology in Q1 2025 and has held it in 7 quarters since.
  • Farther Finance Advisors's Cullinan Oncology position peaked at $15.5K in Q2 2026.
  • 4 funds tracked by Wall St. Rank held Cullinan Oncology as of Q3 2026.

Based on Farther Finance Advisors's 13F filing for Q3 2026, filed 8 Oct 2026.